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Background: The effects of inductive hyperthermia on lung cancer have yet to be fully 
investigated. Magnetic nanoparticles used in inductive hyperthermia are made-to-order and 
expensive. This study was performed to investigate the use of ferucarbotran in inductive hyper-
thermia and to clarify whether inductive hyperthermia using ferucarbotran promotes antitumor 
effects in vivo using a lung cancer cell line.
Methods: We injected A549 cells subcutaneously into the right thighs of BALB/c nu/nu nude 
mice. Forty mice with A549 xenografts were then classified into three groups. Group 1 was the 
control group. All mice in groups 2 and 3 had ferucarbotran injected into their tumors, and mice 
in group 3 were then subjected to alternating magnetic field irradiation. We evaluated tumor 
temperature during the hyperthermic procedure, the time course of tumor growth, histologic 
findings in tumors after hyperthermic treatment, and adverse events.
Results: Intratumor temperature rose rapidly and was maintained at 43°C–45°C for 20 minutes 
in an alternating magnetic field. Tumor volumes in groups 1 and 2 increased exponentially, but 
tumor growth in group 3 was significantly suppressed. No severe adverse events were observed. 
Histologic findings for the tumors in group 3 revealed mainly necrosis.
Conclusion: Inductive hyperthermia using ferucarbotran is a beneficial and promising approach 
in the treatment of lung cancer. Ferucarbotran is a novel tool for further development of induc-
tive hyperthermia.
Keywords: inductive hyperthermia, ferucarbotran, magnetic nanoparticles, alternating magnetic 
field, lung cancer, human use
Introduction
Hyperthermia is a promising approach in the treatment of cancer, and various methods 
have been adopted, including whole body hyperthermia,1 radiofrequency hyperthermia,2 
and induced hyperthermia using a microwave antenna3 or implantable needles.4 
 However, an inevitable technical problem with hyperthermia is the difficulty of uni-
formly heating only the tumor region to the required temperature without damaging 
healthy tissues. Therefore, some researchers have proposed inductive hyperthermia 
using submicron magnetic particles.5,6
The dextran magnetite complex is a submicron magnetic particle that consists 
mainly of magnetic nanoparticles coated with dextran which generate heat in an 
alternating magnetic field by both Brownian and Néel relaxation.7,8 These magnetic 
nanoparticles have been widely studied to improve adsorption activity, heat-generating 
efficiency, and accumulation in tumor cells due to electrostatic interaction with the 
cell membrane.6,9–11 Although excellent magnetic nanoparticles overcoming these 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
237
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S42815
OncoTargets and Therapy 2013:6
difficulties have emerged, they are made-to-order and 
expensive.6 Therefore, more practical magnetic nanoparticles 
are currently in demand.
In this study, we used ferucarbotran, a magnetic resonance 
imaging contrast agent reported to be able to generate heat in 
an alternating magnetic field.12–15 Although there have been 
numerous studies on the effects of inductive hyperthermia 
in various cancers,10,16,17 the effects on lung cancer have yet 
to be investigated fully. In this study, we performed animal 
experiments using nude mice with lung cancer xenografts 
for the following purposes: to reconfirm that commercially 
available ferucarbotran can generate heat in an alternating 
magnetic field and to clarify whether inductive hyperthermia 




Ferucarbotran consists mainly of a hydrophilic colloidal 
solution of superparamagnetic iron oxide coated with 
carboxydextran. It is a complex composed of ultrafine (7 nm 
diameter) magnetite particles and alkali-treated dextran.6 
Ferucarbotran, which is inexpensive and readily available 
(Nihon Schering KK, Osaka, Japan) is typically used in 
medical practice as a magnetic resonance imaging contrast 
agent (Resovist® one vial, 1.6 mL; ferucarbotran, 540 mg/mL; 
27.9 mg Fe/mL or 496 µmol Fe/mL).18
Cell line
The human A549 non-small cell lung cancer cell line was 
used in this study. The A549 cells were obtained from 
the American Type Culture Collection, maintained in 
RPMI-1640 medium supplemented with 10% fetal bovine 
serum, 5 mM nonessential amino acids, and antibiotics 
(penicillin 100 U/mL and streptomycin 100 µg/mL) at 37°C 
in a 5% CO
2
 and 95% air incubator, and subcultured by 
harvesting with trypsin-EDTA.
Development of xenografts
All animal experiments were approved by the Animal Care 
and Use Committee of Kanazawa University. Forty BALB/c 
nu/nu athymic female nude mice aged 4 weeks and weigh-
ing approximately 20 g were used in this study, and were 
purchased from Sankyo Laboratory Service (Toyama, Japan). 
All mice were injected with cell suspensions, consisting 
of approximately 1 × 107 cells in 0.1 mL of phosphate-
buffered saline, subcutaneously into the right thigh. When 
the maximum diameter of the tumors reached 10 mm after 
transplantation, the hyperthermic experiments were started. 
All mice were randomly divided into three groups. Group 1 
(n = 16) was the control group without treatment. Mice in 
group 2 (n = 8) had ferucarbotran injected into their tumors 
without alternating magnetic field irradiation. Mice in group 3 
(n = 16) were injected with ferucarbotran and subjected to 
alternating magnetic field irradiation once only. A smaller 
number of mice were assigned to group 2 because the safety 
of ferucarbotran alone has already been established.13,18–20 
Tumor volumes (V) were measured three times per 
week and calculated using the formula: V = π/6 × larger 
diameter × (smaller diameter)2, as reported previously.21 
Tumor volumes were evaluated for one month after the start 
of hyperthermic treatment.
Inductive hyperthermia
All procedures in animals were performed under anesthesia 
using 2% pentobarbital sodium (Nembutal®, Dainippon 
Sumitomo Pharma, Osaka, Japan) administered by 
intraperitoneal injection (50 mg/kg). Reportedly, the lethal 
dose of ferucarbotran solution in mice is more than 10 mmol 
Fe/kg (558 mg Fe/kg; Resovist 20 mL/kg).13 Ferucarbotran 
was injected into the core of the tumors in all mice only 
once, immediately before alternating magnetic field irra-
diation at a dose of 150 µL, which is equivalent to Resovist 
7.5 mL/kg. A newly developed powerful induction heat-
ing device comprising a high-frequency power source and 
an applicator (Figure 1A)13 was then used to generate an 
alternating current 142 kHz magnetic field from an electric 
Figure 1 Portable induction heating device. (A) Dimensions are height 173 cm, 
width 73 cm, and length 83 cm; weight is 150 kg, and it has a wheel carriage. (B-1) 
It is composed of a high-frequency power source and an applicator, which creates 
an alternating current 142 kHz magnetic field from an electric current in a pancake 
coil. (B-2) The center of the tumor in each mouse was 2 cm distant from the surface 
of the applicator. 
Note: The strength of the magnetic field is 20–24 mTesla at this position.
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current (maximum 440 amps) in a pancake coil (diameter 
240 mm; five turns). The power consumption of this device 
is 3.5 kW with use of a single-phase alternating current 
200 V (Figure 1B-1). For safe use in humans, this device 
adheres to the guidelines of the International Commission on 
Non-Ionizing Radiation Protection for limiting exposure to 
time-varying electric, magnetic, and electromagnetic fields at 
a distance of 1.5 m from the applicator.22 We set the surface 
of the applicator 2 cm from the center of the tumor in each 
mouse. The strength of the magnetic field is 20–24 mTesla 
at this position (Figure 1B-2). Under these conditions, tem-
peratures in the peripheral regions of the tumors (distant side 
to rectum) were measured using an optical fiber thermometer 
(FL-2000, Anritsu Meter Co, Ltd, Tokyo, Japan) during the 
hyperthermic procedures. At the same time, rectal tempera-
tures were monitored to reflect normal tissue temperature. 
The rationale for hyperthermia is based on the direct cell-
killing effects observed at temperatures above 42.5°C,23 
so intratumor temperature was adjusted to 43°C–45°C for 
20 minutes in the alternating magnetic field to avoid overheat-
ing or underheating. We evaluated tumor size and observed 
any adverse events of inductive hyperthermia for 28 days 
after the start of hyperthermic treatment.
Histologic examination
On day 7 following hyperthermic treatment, two mice in 
each group were euthanized for histologic examination. The 
tumors were resected, fixed with 10% formalin solution, and 
sectioned longitudinally. Tumor specimens were stained with 
hematoxylin and eosin, and the condition of the cells around 
ferucarbotran was subsequently evaluated.  Following staining 
with hematoxylin and eosin, tumor specimens from all groups 
were examined for apoptosis by a TUNEL (TdT-mediated 
dUTP-biotin nick-end labeling) assay using the DeadEnd™ 
Colorimetric TUNEL system (Promega, Madison, WI, 
USA), in accordance with the manufacturer’s instructions. 
Apoptosis was evaluated using the apoptotic index, as reported 
previously.24 Briefly, 500 cells were counted in each specimen, 
and the apoptosis index was defined as:
Apoptotic index (%) = 100 × apoptotic cells/total cells.
Statistical analysis
The statistical analysis was performed using Statview 
version 5.0 software (SAS Institute Inc, Cary, NC, USA). 
The statistical significance of tumor growth between the 
three groups was evaluated using the Mann–Whitney U test. 
P , 0.05 was considered to be statistically significant.
Results
Antitumor effects of inductive 
hyperthermia
The time course of tumor growth in each group is shown in 
Figure 2. Tumor volumes in groups 1 and 2 increased expo-
nentially with no regression, and no significant differences 
were observed between tumor volumes on day 28 in groups 1 
and 2 (P = 0.517). Tumor volume on day 28 after treatment 
in group 3 was significantly suppressed when compared with 
that in groups 1 and 2 (group 1 versus group 3, P = 0.0002; 
group 2 versus group 3, P = 0.016). However, complete 





























Figure 2 Time courses of tumor growth in each therapeutic group. 
Note: Data points and error bars indicate means and standard errors of tumor volumes for all xenografts in each therapeutic group.
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Measurement of temperature
To evaluate the selectivity of heating in our hyperthermic 
treatment, the temperatures in both tumor and normal tissue 
(rectum) were measured. Intratumor and rectal temperatures 
during the hyperthermic procedures are shown in Figure 3. 
Intratumor temperature in group 3 rose rapidly and reached 
over 43°C within 2.5 minutes. The temperature was main-
tained at 43°C–45°C for 20 minutes in an alternating mag-
netic field. In contrast, rectal temperatures did not increase 
in an alternating magnetic field.
Histologic findings
Representative microscopic findings for the tumor cells in each 
group are shown in Figure 4. Hematoxylin and eosin staining 
of tumor cells around ferucarbotran in group 3 revealed broad 
necrosis after hyperthermic treatment (Figure 4C), whereas 
tumor cells in groups 1 and 2 showed no necrosis (Figure 4A 
and B). Representative TUNEL staining of tumor cells in 
each group is shown in Figure 5. The positive control for 
TUNEL staining (tumor cells treated with DNase) is shown in 
Figure 5A. Few tumor cells were positive for TUNEL staining 
in groups 1 and 2 (Figure 5B and C). The apoptotic index 
in groups 1 and 2 was 1.78% ± 0.66% and 1.72% ± 0.79%, 
respectively. Further, the apoptotic index in group 3 was 
2.42% ± 0.85%, similar to groups 1 and 2 in TUNEL staining 
(Figure 5D). There was no significant difference between 
groups 1, 2, and 3 (P . 0.05). These findings suggest that 
inductive hyperthermia using ferucarbotran causes mainly 
necrosis but not apoptosis in tumor cells.
Adverse events
No treatment-related deaths or toxicities related to injec-
tion of ferucarbotran were reported. Three of 14 mice in 
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Figure 3 Time courses of intratumoral temperature for four representative xenografts in group 3. 
Note: Bold lines indicate intratumoral temperatures and thin lines indicate rectal temperatures.
severe adverse events, such as ulcers in the region of heat-
ing, growth impairment, or loss of a leg, were observed. No 
adverse events were seen in animals from groups 1 or 2.
Discussion
We demonstrated the activity and safety of inductive 
hyperthermia using clinically available ferucarbotran in the 
treatment of lung cancer xenografts in an in vivo model. Our 
results indicate that inductive hyperthermia using ferucar-
botran stably heated the whole tumor to approximately 45°C 
during most of the treatment period (Figure 3), and subse-
quently induced mainly necrosis of tumor cells, as reported 
previously.25,26 Hyperthermia at temperatures above 44°C has 
been reported to cause necrosis of tumor cells.25,26 Further 
similar results have been reported in inductive hyperthermia 
models in vivo. Takamatsu et al13 reported that induction 
heating using ferucarbotran did not increase apoptosis in 
treated tumor cells, and Wang et al27 reported that most 
tumor cells heated to a higher temperature became necrotic 
in response to inductive hyperthermia, as we demonstrated in 
this study. In contrast, normal tissues without ferucarbotran 
were not heated in an alternating magnetic field. These 
findings indicate stable, efficient, and selective heating by 
inductive hyperthermia using ferucarbotran.
The safety and permissible dose of ferucarbotran in 
medical practice has already been established.18–20 Although 
there are numerous magnetic nanoparticles used in inductive 
hyperthermic experiments, most of them are not approved 
for human use, and only a few safe magnetic nanoparticles, 
such as ferumoxides (Feridex®, AMAG Pharmaceuticals Inc, 
Lexington, MA, USA), have been developed for medical 
practice. Although the ferumoxides approved as a magnetic 
resonance imaging contrast agent produce heat in an alter-
nating magnetic field, we confirmed that the heat-generating 
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efficiency of ferucarbotran in an alternating magnetic field 
was superior to that of ferumoxides in a preliminary in vitro 
study (data not shown). Therefore, we consider that inductive 
hyperthermia using ferucarbotran is a beneficial and feasible 
hyperthermic approach.
Experimental and clinical studies have indicated that 
heat plays a crucial role in human lung cancer.28–30 However, 
despite promising results, hyperthermia has yet to be estab-
lished as a routine clinical treatment due to lack of availability 
of safe magnetic nanoparticles and techniques for clinical 
hyperthermia. The effects of inductive hyperthermia on lung 
cancer xenografts have been investigated, and reported to 
be promising by Hu et al.28,29 However, the magnetic nano-
particles used in their studies were approved for laboratory 
use, but not for human use. Inductive hyperthermia using 
clinically available ferucarbotran had marked antitumor 
effects on lung cancer xenografts, and the effectiveness of our 
hyperthermia strategy was similar to that of previous studies 
using magnetic nanoparticles for laboratory use.
Moreover, we used not only ferucarbotran in this study, 
but also a powerful and safe induction heating machine 
developed for human use.13 Our results strongly suggest that 
inductive hyperthermic treatment using a combination of 
clinically available and safe ferucarbotran and machines has 
the potential for application in clinical settings. To develop 
inductive hyperthermia for lung cancer further, we need to 
deliver ferucarbotran to target tumor sites selectively using 
clinically available techniques. One possible solution to this 
problem is delivery of ferucarbotran to the feeding arter-
ies of tumors using transcatheter arterial embolization, as 
previously reported.13 Furthermore, computed tomography-
guided percutaneous injection of ferucarbotran or endobron-
chial ultrasound-guided transbronchial injection into target 
tumors using bronchoscopy can be used to assess the exact 
location of the ferucarbotran injection. These techniques 
may enable delivery of ferucarbotran selectively to target 
tumor sites.
Finally, despite the satisfactory antitumor effects and 
many advantages of ferucarbotran, complete tumor sup-
pression was not observed in this study. In previous studies, 
tolerable hyperthermia alone was reported to be insufficient 
for complete suppression of tumors,27,31 so combination 
therapy with hyperthermia is necessary for complete tumor 
suppression. We are continuing our search for suitable drugs 
to use concomitantly with inductive hyperthermia and feru-
carbotran to enhance the antitumor effects.
This study has several limitations. First, we only heated 
the tumors to 45°C to avoid thermal damage to other organs, 
particularly in an animal as small as the nude mouse. 
Therefore, the effects of induction heating at higher tem-
peratures are unknown. Second, the surface of the induction 
heating applicator was set at 2 cm from the target lesions, 
which is too superficial to reflect deep organ cancers in adult 
humans in clinical practice. Further investigation is needed 
to confirm the effectiveness and safety of this method in the 
treatment of lung cancer in humans.
Conclusion
Inductive hyperthermia using ferucarbotran is a beneficial 
and promising approach in the treatment of lung cancer. 
Figure 4 Microscopic appearances of tumor specimens. (A and B) Necrosis was 
not induced in tumors in group 1 or 2 (hematoxylin and eosin staining, ×200). 
(C) Ferucarbotran was injected into tumors (arrows) and tumor cells around 
ferucarbotran in group 3 showed broad necrosis after inductive hyperthermia 
(arrowheads, hematoxylin and eosin staining, ×200 field).
A C
DB
Figure 5 TUNEL staining of tumors in each group. (A) Positive control for TUNEL 
staining. Brown staining cells indicate TUNEL-positive cells, (B) group 1, and (C) 
group 2. Irradiation of alternating magnetic field alone or injection of ferucarbotran 
alone did not induce apoptosis in lung cancer cells. (D) In group 3, inductive 
hyperthermia did not increase apoptotic cells around ferucarbotran (arrows) 
compared with groups 1 or 2 (TUNEL staining ×200 field).
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Ferucarbotran is a novel tool needing further development 
in inductive hyperthermia.
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